Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.prevestdenpro.com | |
Market Cap | 527.71 Cr. | |
Enterprise Value(EV) | 527.71 Cr. | 2023-03 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 13.09 | Trailing Twelve Months Ending 2023-03 |
Price-Earning Ratio (PE) | 33.59 | Trailing Twelve Months Ending 2023-03 |
Industry PE | 53.45 | Trailing Twelve Months Ending 2023-03 |
Book Value / Share | 60.65 | Trailing Twelve Months Ending 2023-03 |
Price to Book Value | 7.25 | Calculated using Price: 439.65 |
Dividend Yield | 0.00 | Period Ending 2022-03 |
No. of Shares Subscribed | 1.20 Cr. | 12,003,000 Shares |
FaceValue | 10 | |
About Prevest Denpro Ltd. | ||
The company manufactures and markets a range of dental materials for diagnosing, treating, and preventing dental conditions and improving the aesthetics of the human smile. |
1 Day |
|
-0.60% |
1 Week |
|
+4.37% |
1 Month |
|
+8.22% |
3 Month |
|
+34.79% |
6 Month |
|
+11.97% |
1 Year |
|
+33.29% |
2 Year |
|
|
5 Year |
|
|
10 Year |
|
5 years | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 29.72 | 34.02 | 39.13 | 38.13 | 29.07 | |
Return on Capital Employed (%) | 37.15 | 39.27 | 45.63 | 46.96 | 39.64 | |
Return on Assets (%) | 18.88 | 22.30 | 27.50 | 27.85 | 24.40 |
Particulars | 6 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03* Rs. Cr. |
Shh. Funds | 7 | 10 | 15 | 23 | 57 | 73 | |
Non Curr. Liab. | 1 | 2 | 2 | 2 | 2 | 0 | |
Curr. Liab. | 3 | 3 | 4 | 7 | 5 | 5 | |
Minority Int. | |||||||
Equity & Liab. | 12 | 15 | 21 | 31 | 64 | 79 | |
Non Curr. Assets | 4 | 5 | 6 | 7 | 11 | 24 | |
Curr. Assets | 7 | 10 | 16 | 24 | 53 | 54 | |
Misc. Exp. not W/O | |||||||
Total Assets | 12 | 15 | 21 | 31 | 64 | 79 |
Particulars | 6 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. TTM |
Net Sales | 17 | 19 | 23 | 28 | 38 | 50 | |
Other Income | 1 | 0 | 2 | 1 | 2 | 2 | |
Total Income | 18 | 20 | 25 | 30 | 40 | 52 | |
Total Expenditure | -14 | -15 | -18 | -19 | -23 | -30 | |
PBIDT | 4 | 4 | 7 | 10 | 17 | 22 | |
Interest | 0 | 0 | 0 | 0 | 0 | ||
Depreciation | 0 | 0 | 0 | 0 | -1 | -1 | |
Taxation | -1 | -1 | -1 | -2 | -4 | -5 | |
Exceptional Items | |||||||
PAT | 2 | 3 | 5 | 7 | 12 | 16 | |
Adjusted EPS | 76 | 105 | 176 | 8 | 10 | 13 |
Particulars | 5 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 2 | 3 | 5 | 9 | 7 | |
Cash Fr. Inv. | -1 | -1 | -1 | -2 | -4 | |
Cash Fr. Finan. | 0 | 0 | 0 | -1 | 23 | |
Net Change | 1 | 2 | 4 | 6 | 26 | |
Cash & Cash Eqvt | 4 | 6 | 10 | 16 | 42 |
Mon, 22 May 2023
Intimation Of Incorporation Of Subsidiary Company-Denvisio Biomed Limited Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. - Intimation of incorporation of Subsidiary Company. |
Tue, 16 May 2023
Statement Of NIL Deviation Or Variation In The Use Of Proceeds Of Initial Public Offer Pursuant to the aforesaid SEBI Listing Regulations please find enclosed Statement confirming that there are no deviation(s) or variation(s) in respect of utilization of proceeds of Initial Public Offer of the Company for the quarter ended March 31 2023 as mentioned in the object clause of the offer letter of the issue. |
Tue, 16 May 2023
Statement Of NIL Deviation Or Variation In The Use Of Proceeds Of Initial Public Offer Pursuant to the aforesaid SEBI Listing Regulations please find enclosed Statement confirming that there are no deviation(s) or variation(s) in respect of utilization of proceeds of Initial Public Offer of the Company for the quarter ended December 31 2022 as mentioned in the object clause of the offer letter of the issue. |
Fri, 26 May 2023 |
|
|
|
|
|